For Merck's HPV vaccine Gardasil, should we prioritize expanding age range recommendations or focusing on improving uptake in the current target population?

Introduction

The trade-off we're examining today is whether Merck should prioritize expanding age range recommendations for their HPV vaccine Gardasil or focus on improving uptake in the current target population. This decision is crucial for Merck's product strategy and has significant implications for public health. I'll analyze this trade-off by examining the product context, potential impacts, key metrics, and experimental approaches to inform our decision-making process.

Step 1

Clarifying Questions (3 minutes)

• Based on recent market trends, I'm thinking Gardasil might be facing increased competition. Could you provide an overview of the current competitive landscape for HPV vaccines?

Why it matters: Helps understand external pressures influencing our strategy Expected answer: Limited competition with 1-2 major players Impact on approach: Would influence whether we focus on market share or market expansion

• Considering Gardasil's current market position, I'm curious about its revenue contribution to Merck's portfolio. How significant is Gardasil to Merck's overall financial performance?

Why it matters: Indicates the strategic importance of this decision Expected answer: Significant contributor, top 5 product Impact on approach: Higher contribution would justify more aggressive expansion strategies

• Looking at user behavior, I'm wondering about the current vaccination rates in the target population. What percentage of the eligible population is currently receiving the full course of Gardasil?

Why it matters: Helps quantify the potential for improvement in current target group Expected answer: Moderate uptake, around 50-60% Impact on approach: Lower rates might suggest focusing on current population first

• Considering potential age range expansion, I'm curious about the regulatory landscape. What's the typical timeline and process for getting approval for new age groups?

Why it matters: Affects feasibility and timeline of expansion strategy Expected answer: 12-18 months for regulatory approval Impact on approach: Longer timelines might favor focusing on current population in short term

• Thinking about resource allocation, I'm interested in understanding our current marketing and distribution capabilities. How much additional capacity do we have to support either expanded age ranges or increased uptake efforts?

Why it matters: Determines feasibility of executing on either strategy Expected answer: Some additional capacity, but would require reallocation Impact on approach: Limited capacity might favor focusing on one strategy over trying both